Plaintiffs Point To "Tellabs" In Pfizer Securities Suit

Law360, New York (July 12, 2007, 12:00 AM EDT) -- The lead plaintiffs in a securities fraud lawsuit against Pfizer Inc. over the drug giant's decision to scrap its highly anticipated cholesterol drug torcetrapib moved to bolster their case Wednesday, arguing that a recent U.S. Supreme Court decision lends weight to their scienter allegations.

Attorneys with Schoengold Sporn Laitman & Lometti, P.C., the firm representing the plaintiffs in the case, said in court documents filed in the U.S. District Court for the Southern District of New York that the High Court's June 21 decision in Tellabs...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.